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doi:10.1016/j.jfma.2011.07.014Background/Purpose: The immunogenicity and safety of the 10-valent pneumococcal non-
typeable Haemophilus influenzae (H. Influenzae) protein D conjugate vaccine (PHiD-CV),
co-administered with routine childhood vaccines, were assessed in Taiwanese infants.
Methods: In this open study, 230 healthy infants were primed with three doses of PHiD-CV
(Synflorix) and diphtheria, tetanus, acellular pertussis, hepatitis B (HBV), inactivated poliomy-
elitis and Haemophilus influenzae type b (Hib) conjugate vaccine (DTPa-HBV-IPV/Hib vaccine)
at 1.5, 3 and 6 months of age and two doses of oral human rotavirus vaccine at 1.5 and 3
months. Pneumococcal immune responses were assessed 1 month post-dose three, by 22F-inhi-
bition ELISA and opsonophagocytic activity (OPA) assay. Local and general solicited/unsolicited
symptoms and serious adverse events (SAEs) were recorded.
Results: At least 95.4% of participants had an antibody concentration 0.2 mg/mL against each
vaccine serotype. At least 96.1% of participants had an OPA titer 8 against each vaccine sero-
type except 6B (87.3%). All infants, but one, were seropositive for antibodies against nontype-
able H. influenzae protein D. Immune responses to the co-administered vaccines were goodfectious Diseases, Department of Pediatrics, National Taiwan University Hospital, Taipei 100, Taiwan.
.tw (L.-M. Huang).
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496 T.-Y. Lin et al.and in line with previous reports. PHiD-CV was well tolerated, with low (6.3%) incidences of
grade 3 solicited local symptoms. The frequencies of general symptoms were in line with other
pneumococcal conjugate vaccine studies. There were no systematic increases in incidences of
solicited general or local symptoms with successive doses. There were no reports of grade 3
fever (rectal temperature > 40 C) or SAEs considered to be causally related to vaccination.
Conclusion: PHiD-CV co-administered with routine childhood vaccines within the first 6 months
of life, was highly immunogenic, and well tolerated in Taiwanese infants.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Infections caused by Streptococcus pneumoniae (S. pneu-
moniae) are a major cause of morbidity and mortality all
over the world. Bacteremia, meningitis and sepsis are the
most common manifestations of invasive pneumococcal
disease (IPD), whereas bacterial spread within the respi-
ratory tract can result in otitis media, sinusitis, bronchitis
and pneumonia.1
The emergence of antimicrobial-resistant pneumococci
in many countries is a major concern.2 Taiwan is an area
with high a prevalence of penicillin- and macrolide-
resistant S. pneumoniae.3,4 One nationwide susceptibility
study of S. pneumoniae isolates collected from intensive
care units in Taiwan, showed non-susceptibility to penicillin
(as defined by meningitis antibiotic non-susceptibility
criteria) increased from 58% in 2000 to 85% in 2005.4 The
2005 survey also found that 63% of S. pneumoniae isolates
were resistant to azithromycin. A similar rate of penicillin
non-susceptibility (83%) was reported in a study of 364
clinical S. pneumoniae isolates collected from 2003 to 2006
in Taiwan, while 91% of isolates were resistant to erythro-
mycin.3 Furthermore, an examination of IPD in Taiwanese
children in the period 2001e2006 showed that most
episodes (86%) occurred in children aged <5 years, and
penicillin resistance was an independent predictor of
mortality.5 Among Taiwanese children aged 5 years, S.
pneumoniae serogroups 6, 14, 19 and 23 appeared most
prevalent6,7 and at the same time showed the lowest
penicillin susceptibility rates.6,7 Moreover, in studies of
nasopharyngeal carriage, isolates from Taiwanese children
attending day-care centers or kindergartens had a high
prevalence of penicillin non-susceptible pneumococci, with
rates > 70%.8,9
The 10-valent pneumococcal conjugate vaccine [PHiD-
CV; Synflorix, GlaxoSmithKline (GSK) Biologicals, Rixensart,
Belgium] contains pneumococcal serotypes 1, 5 and 7F in
addition to the 7 serotypes (4, 6B, 9 V, 14, 18C, 19F, 23F),
present in the licensed 7-valent pneumococcal conjugate
vaccine (7vCRM; Prevenar/Prevnar, Pfizer Inc., New York,
USA). Eight of the 10 serotypes in PHiD-CV are conjugated
to protein D, a highly conserved cell surface lipoprotein of
nontypeable Haemophilus influenzae (NTHi). Protein D was
selected to avoid carrier interference known to occur
with some conjugates that have tetanus toxoid or CRM197
as the carrier protein10 and for its potential to provide
protection against NTHi infections.11 The protective
potential of protein D against NTHi disease, when used as
a carrier protein for pneumococcal polysaccharides, was
previously confirmed with an experimental 11-valentvaccine formulation in a double-blind, randomized study
of nearly 5000 infants assessing vaccine efficacy against
acute otitis media (AOM).12
Co-administration of individual vaccines helps minimize
the number of immunization visits and might improve
compliance with vaccine recommendations, but evidence is
required to show that vaccine immunogenicity and safety
are not compromised. Previous primary and booster vacci-
nation studies showed that PHiD-CV was immunogenic and
well tolerated when co-administered with other routinely
used pediatric vaccines.13e20 This primary immunization
trial conducted in Taiwan assessed the immunogenicity and
safety of PHiD-CV in infants when co-administered with two
vaccines: combined hexavalent DTPa-HBV-IPV/Hib vaccine
(Infanrix hexa, GSK Biologicals) and oral live attenuated
human rotavirus (HRV) vaccine (Rotarix, GSK Biologicals).
Materials and methods
Study design and participants
This was a single-arm, open study (109861/NCT00533507)
conducted to assess the immunogenicity, safety and reac-
togenicity of PHiD-CV co-administered with DTPa-HBV-
IPV/Hib and HRV vaccines in Taiwanese infants. The
immunogenicity of both co-administered vaccines was also
assessed. The study was carried out between 18 September,
2007 and 6 June, 2008 in three centers in Taiwan, and was
conducted according to Good Clinical Practice guidelines
and the Declaration of Helsinki. The study protocol was
approved by a national ethics committee and institutional
review boards of the participating centers. Written
informed consent was obtained from the parents/guardians
of each infant before enrollment.
Healthy infants aged between 6 and 8 weeks at the time
of first vaccination and born after a gestation period
between 36 and 42 weeks, were enrolled in the study.
Infants were excluded from participation if they had
received previous vaccination against diphtheria, tetanus,
pertussis, polio, H. influenzae type b (Hib), rotavirus and/
or S. pneumoniae. Infants were also excluded if they had
a history of diphtheria, tetanus, pertussis, hepatitis B, polio
or Hib disease. Gastroenteritis within 7 days before vaccine
administration warranted deferral of vaccination.
Vaccines
PHiD-CV (Synflorix, GlaxoSmithKline Biologicals, Rixensart,
Belgium) contained 1 mg of each capsular polysaccharide of
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and 3 mg of serotype 4, conjugated individually to NTHi
protein D; 3 mg of serotype 18C capsular polysaccharide
conjugated to tetanus toxoid; and 3 mg of serotype 19F
capsular polysaccharide conjugated to diphtheria toxoid.
The DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) contained
diphtheria toxoid 30 IU, tetanus toxoid 40 IU, pertussis
toxoid (PT) 25 mg, filamentous hemagglutinin (FHA) 25 mg,
pertactin (PRN) 8 mg, recombinant hepatitis B surface
antigen (HBs) 10 mg, poliovirus type 1 (Mahoney strain) 40 D
antigen units, poliovirus type 2 (MEF-1 strain) 8 D antigen
units, poliovirus type 3 (Saukett strain) 32 D antigen units
and Hib polysaccharide polyribosylribitol phosphate (PRP)
10 mg conjugated to tetanus toxoid 20e40 mg. The oral live
attenuated HRV vaccine (Rotarix) contained RIX4414 HRV
strain not less than 106.0CCID50. Using standard vaccination
techniques, PHiD-CV and DTPa-HBV-IPV/Hib vaccine were
administered by intramuscular injection into the thigh.
Vaccine doses were administered at approximately 6e8
weeks, 3 and 6 months of age. After the three vaccination
visits, there was a follow-up visit at approximately 7
months of age (Fig. 1).
Immunogenicity assessment
Two blood samples were collected from all infants: before
the first vaccine dose and 1 month after the third vaccine
dose at approximately 7 months of age (Fig. 1). Serum
samples were stored at e20 C until analyzed at GSK Bio-
logicals laboratories.
GSK’s 22F-inhibition enzyme-linked immunosorbent assay
(22F-ELISA) was used to measure serum anti-pneumococcal
serotype-specific total immunoglobulin G (IgG) concentra-
tions, as described before,21,22 with an assay cut-off of
0.05 mg/mL. It was established previously that an antibody
concentration of 0.2 mg/mL measured by GSK’s 22F-ELISA
is equivalent to 0.35 mg/mL, as determined by the WHO
reference laboratory ELISA without 22F-inhibition22,23 and
therefore corresponds to the threshold proposed by the
WHO for non-inferiority comparison between pneumo-
coccal conjugate vaccines.24,25
Opsonophagocytic activity (OPA) was measured in a
randomly selected subset of 115 infants by a pneumococcal
killing assay using a HL60 cell line.26 The results were
presented as the dilution of serum (opsonic titer) able to
sustain 50% killing of live pneumococci under the assayX X
Visit 1
6–8 wk
Vaccination: Dose 1
PHiD-CV
DTPa-HBV-IPV/Hib
HRV
Visit 2
3 mo
Dose 2
PHiD-CV
DTPa-HBV-IPV/Hib
HRV
Infant age:
35–63 days 7
Intervals between 
study visits:
Blood sample 
collection
Figure 1 Study visits andconditions. The cut-off of the assay was an opsonic titer of
8.27 Antibody responses were also determined for the
pneumococcal cross-reactive serotypes 6A and 19A. IgG
antibodies against NTHi protein D were measured in all
individuals by an in-house ELISA; the assay cut-off was 100
EL.U/mL.
Immune responses to the co-administered DTPa-HBV-
IPV/Hib vaccine antigens [except inactivated poliovirus
(IPV)] were tested in 50% of individuals not included in the
OPA assay subset. Immune responses to IPV and HRV were
tested in the remaining participants. Immune responses to
the DTPa-HBV-IPV/Hib vaccine were measured by ELISA,
multiplex techniques or (for poliovirus) virus micro-
neutralization test. The assay cut-off was 0.15 mg/mL for
antibodies against Hib polysaccharide PRP, 5 EL.U/mL for
IgG antibodies against pertussis components PT, FHA and
PRN, 0.1 IU/mL for anti-diphtheria and anti-tetanus anti-
bodies, and a serum dilution of 1:8 for antibodies against
poliovirus types 1, 2 and 3.
Antibodies against HBs were determined using a GSK
Biologicals ELISA, with a cut-off for seroprotection of
10 mIU/mL. Anti-HRV immunoglobulin A (IgA) antibody
concentrations were measured by ELISA, with a cut-off of
20 U/mL.
Reactogenicity and safety assessment
Reactogenicity and safety were evaluated in all infants
using diary cards that were completed by their parents or
guardians. Specific adverse events (AEs) commonly associ-
ated with injectable childhood vaccines were actively
solicited for 4 days (days 0e3) following each vaccine dose.
These included local (pain, redness and swelling at the
injection sites) and general (drowsiness, irritability, loss of
appetite, fever) symptoms. Fever was defined as rectal
temperature 38.0 C. Diarrhea and vomiting were also
solicited due to the co-administration of the HRV vaccine.
Other non-serious and unsolicited AEs were recorded within
a 31-day (days 0e30) follow-up period after each vaccine
dose. Serious AEs (SAEs), recorded during the entire study
period, were defined as any event resulting in death, any
life-threatening event or any event causing disability, or
requiring hospitalization or prolongation of hospitalization.
The intensity of each solicited symptom was graded on
a scale from 0 to 3. Pain at the injection site was considered
to have a grade 3 intensity if the child cried when the limbX X
Visit 3
6 mo
Dose 3
PHiD-CV
DTPa-HBV-IPV/Hib
Visit 4 (follow-up)
7 mo
7–110 days 30–42 days
Blood sample 
collection
vaccination schedule.
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redness and swelling at the injection site, if the diameter
was > 30 mm, and if the rectal temperature was > 40 C.
Irritability/fussiness was considered of grade 3 intensity if
the child cried and could not be comforted or if normal
activity was prevented, and loss of appetite was considered
grade 3 if the child did not eat at all. Grade 3 for diarrhea
was 6 looser than normal stools/day and for vomiting 3
episodes/day. Grade 3 intensity for all other symptoms and
AEs was defined as preventing normal everyday activity,
such as preventing attendance at the day-care center, and/
or causing parents/guardians to seek medical advice.
All solicited local symptoms were defined in the protocol
to be considered causally related to vaccination. Using their
clinical judgment, the investigators assessed the presence
or absence of a possible causal relationship to vaccination
of all other AEs. Use of therapeutic and prophylactic anti-
pyretic medication was permitted.
Statistical analysis
The immunogenicity analysis was performed on the
according-to-protocol (ATP) immunogenicity subset, defined
as vaccinated participants who met all eligibility criteria,
complied with protocol-defined procedures and with anti-
body assay results available. ELISA geometric mean anti-
body concentrations (GMCs) were calculated with 95%
confidence intervals (CIs) for each vaccine serotype and
protein D, before the first vaccine dose and 1 month after
the third vaccine dose, and for the cross-reactive serotypes
6A and 19A 1 month after the third vaccine dose. Geometric
mean OPA titers (GMTs) were calculated with 95% CIs for
all 10 vaccine serotypes, and serotypes 6A and 19A 1
month after the third vaccine dose. For each of the PHiD-CV
pneumococcal serotypes and serotypes 6A and 19A,
percentages of infants with ELISA antibody concentration
0.2 mg/mL and percentages with OPA titer 8 were
calculated with exact 95% CIs. Seropositivity/seropro-
tection rates were calculated with exact 95% CIs for anti-
bodies against the DTPa-HBV-IPV/Hib vaccine antigens 1
month after the third vaccine dose and, for HRV IgA anti-
bodies, 4 months after the second HRV vaccine dose.
Randomization for serological testing was generated at GSK11 not included in according -to-protocol 
immunogenicity cohort:
8 administration of forbidden vaccine(s)
1 protocol violation
1 non-compliance with blood sampling schedule
1 essential serological data missing
219
im
*1 infant was withdrawn following consent withdrawal not due to an  a
Figure 2 TrBiologicals, Rixensart, using a standard SAS (Statistical
Analysis System) program.
The analysis of safety was performed on the total
vaccinated cohort. Incidences of local and general AEs
during the 4-day and 31-day post-vaccination periods were
calculated with exact 95% CIs, after each vaccine dose and
overall, according to the type of symptom, intensity and
relationship to vaccination. The overall incidence of AEs
was calculated as the proportion of study vaccine admin-
istration visits followed by at least one type of symptom.
The prevalence of concomitant antipyretic medication
during the 4-day post-vaccination period was computed
with exact 95% CIs, after each dose and overall. Exact 95%
CIs were calculated using Proc StatXact.
Results
A total of 230 infants were enrolled, of which 229 completed
the study (Fig. 2). One infant had consent withdrawn, which
was not due to an AE. The safety cohort included all 230
infants and the immunogenicity ATP cohort included 219
infants (Fig. 2). Reasons for exclusion from the immunoge-
nicity ATP cohort were: non-compliance with the blood
sampling schedule, missing essential serological data,
protocol violation (1 infant each) and administration of
forbidden vaccine(s) (8 infants). The mean age (SD) of the
immunogenicity ATP cohort at first vaccination was 6.4
(0.58) weeks, 48.9% were female and all were Asian.
Immunogenicity
Pneumococcal antibody responses: One month after the
third vaccine dose, at least 95.4% of PHiD-CV-primed
infants had an antibody concentration 0.2 mg/mL against
serotypes 6B and 23F, and at least 99.5% reached this
threshold for each of the other serotypes contained in
PHiD-CV (Table 1). OPA titer 8 was observed in at least
96.1% of infants against each of the pneumococcal vaccine
serotypes with the exception of serotype 6B (87.3%)
(Table 1).
Post-vaccination, 78.5% had an antibody concentration
0.2 mg/mL for the cross-reactive serotype 6A and 64.7%230 enrolled
230 vaccinated*
 according -to-protocol 
munogenicity cohort
230 safety cohort
dverse event
ial profile.
Table 1 22F-ELISA antibody concentrations and OPA titers against individual pneumococcal vaccine serotypes before vaccination and 1 month after the third vaccine dose
and against cross-reactive serotypes 6A and 19A 1 month after the third vaccine dose (ATP cohort for immunogenicity).
Pre-vaccination 1 mo post-dose 3
ELISA ELISA OPA
n % 0.2 mg/mL
(95% CI)
GMC, mg/mL
(95% CI)
n % 0.2 mg/mL
(95% CI)
GMC, mg/mL
(95% CI)
n % 8
(95% CI)
GMT
(95% CI)
Vaccine serotypes
1 217 13.8 (9.5e19.1) 0.06 (0.05e0.07) 219 100 (98.3e100) 2.92 (2.65e3.22) 102 96.1 (90.3e98.9) 206.6 (158.9e268.6)
4 217 11.5 (7.6e16.5) 0.05 (0.04e0.06) 219 99.5 (97.5e100) 3.79 (3.42e4.19) 103 100 (96.5e100) 1227.4 (1054.7e1428.4)
5 217 27.2 (21.4e33.6) 0.10 (0.08e0.12) 219 100 (98.3e100) 4.50 (4.11e4.93) 102 99.0 (94.7e100) 233.8 (189.6e288.3)
6B 217 24.9 (19.3e31.2) 0.07 (0.06e0.09) 219 95.4 (91.8e97.8) 1.69 (1.47e1.94) 102 87.3 (79.2e93.0) 685.2 (439.8e1067.7)
7F 218 26.6 (20.9e33.0) 0.09 (0.08e0.11) 219 100 (98.3e100) 4.07 (3.72e4.46) 103 100 (96.5e100) 5053.9 (4279.2e5968.8)
9 V 218 22.0 (16.7e28.1) 0.08 (0.07e0.09) 219 100 (98.3e100) 3.90 (3.51e4.32) 98 100 (96.3e100) 2052.9 (1691.4e2491.7)
14 218 61.0 (54.2e67.5) 0.37 (0.30e0.46) 219 99.5 (97.5e100) 5.69 (5.10e6.35) 102 99.0 (94.7e100) 1259.7 (1004.8e1579.1)
18C 219 32.0 (25.8e38.6) 0.11 (0.09e0.13) 219 100 (98.3e100) 7.28 (6.43e8.25) 101 98.0 (93.0e99.8) 319.5 (239.8e425.6)
19F 219 42.5 (35.8e49.3) 0.16 (0.13e0.20) 219 100 (98.3e100) 8.04 (7.37e8.78) 103 98.1 (93.2e99.8) 567.3 (450.7e713.9)
23F 218 13.3 (9.1e18.5) 0.05 (0.05e0.06) 218 97.2 (94.1e99.0) 2.81 (2.44e3.22) 102 96.1 (90.3e98.9) 2542.5 (1832.0e3528.6)
Cross-reactive serotypes
6A e e e 219 78.5 (72.5e83.8) 0.56 (0.46e0.67) 97 89.7 (81.9e94.9) 417.8 (285.8e610.6)
19A e e e 218 64.7 (57.9e71.0) 0.27 (0.23e0.32) 97 39.2 (29.4e49.6) 16.4 (11.2e24.0)
n Z number of participants with available results.
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Table 3 Overall incidences of solicited general adverse
events within 4 days (days 0e3) after vaccination (total
vaccinated cohort).
Symptom Intensity Overall incidence
(n Z 686), % (95% CI)
Irritability Any 61.7 (57.9e65.3)
Grade 3 6.3 (4.6e8.4)
Drowsiness Any 56.0 (52.2e59.7)
Grade 3 1.2 (0.5e2.3)
Loss of appetite Any 41.0 (37.3e44.7)
Grade 3 0.7 (0.2e1.7)
Fever (rectal
temperature)
38.0 C 37.3 (33.7e41.1)
>38.5 C 12.0 (9.6e14.6)
>39.0 C 3.5 (2.3e5.2)
>39.5 C 0.7 (0.2e1.7)
>40.0 C 0.0 (0.0e0.5)
Vomiting Any 10.6 (8.4e13.2)
Grade 3 1.0 (0.4e2.1)
Diarrhea Any 1.0 (0.4e2.1)
Grade 3 0.0 (0.0e0.5)
nZ number of documented doses. Grade 3 Z irritability, child
cried and could not be comforted/prevented normal activity;
drowsiness, prevented normal everyday activity; loss of appe-
tite, child did not eat at all; vomiting, 3 episodes/day; diar-
rhea, 6 looser than normal stools/day.
500 T.-Y. Lin et al.reached this threshold for serotype 19A (Table 1). The
percentages of infants with post-vaccination OPA titer 8
for these cross-reactive serotypes were 89.7% and 39.2%,
respectively (Table 1).
Protein D: Before vaccination, the GMC for antibodies
against NTHi protein D was 62.3 EL.U/mL (95% CI Z
58.1e66.8 EL.U/mL). One month after the third vaccine
dose, all infants, except one (99.5%), were seropositive (
100 EL.U/mL) for anti-protein D antibodies, with a GMC of
2277.6 EL.U/mL (95% CI Z 2048.7e2532.1 EL.U/mL).
Co-administered vaccines: One month after the third
vaccine dose, all participants were seroprotected against
the diphtheria, tetanus, poliovirus types 1, 2 and 3, and HBs
antigens contained in the co-administered DTPa-HBV-IPV/
Hib vaccine. All infants were seropositive for antibodies
against each of the pertussis antigens (PT, FHA and PRN)
and had anti-PRP antibody levels 0.15 mg/mL while 96.6%
had anti-PRP antibody levels 1 mg/mL. Four months after
the second HRV vaccine dose, 86.3% of infants were sero-
positive for anti-HRV antibodies ( 20 U/mL).
Reactogenicity and safety
Overview of adverse events: General symptoms were
more frequently reported than local symptoms during the
31-day follow-up period [overall incidence 82.9% (95%
CI Z 79.9e85.7%) versus 59.8% (95% CI Z 56.0e63.5%)].
The overall incidence of local symptoms was in the same
range for PHiD-CV (53.8%; 95% CI Z 50.0e57.6%) and the
DTPa-HBV-IPV/Hib vaccine (56.2%; 95% CI Z 52.4e60.0%).
Solicited local and general adverse events (4-day post-
vaccination period): The most frequently reported soli-
cited local AE was redness (Table 2). The overall incidence
of grade 3 solicited local AEs was low irrespective of the
injection site, ranging from 0.3% to 3.8%, and incidences of
pain were the same at both injection sites (Table 2). The
most frequently reported solicited general AE was irrita-
bility (61.7%; Table 3). The overall incidence of fever
(rectal temperature 38 C) was 37.3% and there were no
reports of grade 3 fever (rectal temperature > 40 C). The
overall incidence of other grade 3 solicited general AEs
ranged from 0.0% to 6.3% (Table 3), most of which were
considered to be causally related to vaccination. There
were no systematic increases in incidences of solicited
general or local symptoms with successive doses (data not
shown).Table 2 Overall incidences of solicited local adverse events at
days (days 0e3) after vaccination (total vaccinated cohort).
Symptom Intensity
PHiD-CV (n Z 686)
Redness Any 37.9 (34.3e41.6)
>30 mm 0.3 (0.0e1.0)
Pain Any 36.9 (33.3e40.6)
Grade 3 3.8 (2.5e5.5)
Swelling Any 30.2 (26.8e33.8)
>30 mm 0.3 (0.0e1.0)
n Z number of documented doses. Grade 3 pain recorded if infant cAntipyretic medication use was infrequent; 12.7% of
doses were followed by the use of antipyretic medication
during the 4-day post-vaccination period, and no prophy-
lactic use was reported.
Unsolicited and serious adverse events: The overall
incidence of unsolicited AEs was 18.0%. The most frequently
reported unsolicited symptom was upper respiratory tract
infection (overall incidence 9.0%). Only 2 doses (maximum
0.3% overall incidence) were followed by an unsolicited AE
considered to be causally related to vaccination (rash in
both cases). Only 3 unsolicited AEs with grade 3 intensity
were reported (bronchitis, allergic dermatitis and atopic
dermatitis, following 1 dose each), none of which were
considered to be causally related to vaccination.
SAEs were reported in 15 participants during the study
and none was considered to be causally related to vacci-
nation. One SAE (atopic dermatitis) was ongoing at the end
of the study. No fatal SAEs were reported.the PHiD-CV and DTPa-HBV-IPV/Hib vaccination sites within 4
Overall incidence, % (95% CI)
DTPa-HBV-IPV/Hib (n Z 685) Total (n Z 686)
38.8 (35.2e42.6) 43.3 (39.5e47.1)
0.6 (0.2e1.5) 0.7 (0.2e1.7)
36.9 (33.3e40.7) 39.7 (36.0e43.4)
3.5 (2.3e5.2) 4.2 (2.8e6.0)
35.3 (31.7e39.0) 38.3 (34.7e42.1)
0.7 (0.2e1.7) 0.9 (0.3e1.9)
ried when limb was moved/spontaneously painful.
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The results of this study show that PHiD-CV is highly
immunogenic for all vaccine serotypes, when given as
a 3-dose primary vaccination course to young Taiwanese
infants. The immune responses to the 10 vaccine serotypes
were at least as high as those reported in previous
PHiD-CV primary vaccination studies conducted in various
European countries, Chile and the Philippines.13,14,16,17 The
percentages of infants with OPA titer 8 for each vaccine
serotype were also in line with previous reports, although
for serotype 1, the percentage was higher than in previous
European studies (96.1% versus 43.1e65.7%).14,16,17 As
observed in various pneumococcal conjugate vaccine
studies,12,28e30 immunogenicity was weaker for serotype 6B
than for other serotypes. However, experience with other
pneumococcal conjugate vaccines has shown that high
efficacy against IPD or AOM could be obtained even for
serotypes with lower antibody responses.12,28e30
There was also a trend towards stronger ELISA or OPA
antibody responses to the cross-reactive serotypes 6A and
19A in the current study, in comparison with European
PHiD-CV trials.14,16,17 A similar trend was previously
observed when immune responses from studies conducted
in Chile and the Philippines were compared to European
immunogenicity data,13,14,31 and may be due to factors
such as early pneumococcal nasopharyngeal acquisition and
ecological or genetic differences.31
For the 7 serotypes common to PHiD-CV and the 7vCRM
vaccine, immune responses in the current study were in the
same range as reported in PHiD-CV studies which included
a 7vCRM vaccinated group.14,16,17 Moreover, the immuno-
genicity results of the present study are in line with those
from a 7vCRM primary vaccination study conducted in
Taiwan, although comparisons are limited by differences in
study methodologies and laboratory assays.32
All infants, except one, were seropositive for antibodies
against the NTHi derived carrier protein (protein D) and
this response (>99%) was in line with that observed in
previous PHiD-CV trials.13,14,16,17 The potential to address
both pneumococcal and NTHi diseases with PHiD-CV is
noteworthy, given reports of high rates of antimicrobial
resistance in Taiwan for H. influenzae4,33,34 as well as for
S. pneumoniae.3,4 S. pneumoniae and NTHi are the most
common causes of bacterial AOM.35 In a study with an
11-valent protein D conjugate vaccine formulation, signifi-
cant protective efficacy was reported for episodes of AOM
caused by pneumococcal vaccine serotypes and by NTHi.12
There was no evidence in previous primary and booster
PHiD-CV vaccination studies of negative interference on
the immune response to any of the co-administered vaccine
antigens when compared with immune responses after
7vCRM co-administration.36 Although our study was not
designed to assess potential immunological interferences
between the different co-administered vaccines, the
excellent immunogenicity for all co-administered antigens,
with seroprotection/seropositivity results in line with
previous studies with the DTPa-HBV-IPV/Hib37 and HRV
vaccines,38 suggest that no clinically relevant interference
would have occurred.
PHiD-CV presented an acceptable safety profile and was
well tolerated, with low incidences of grade 3 solicitedlocal AEs. The incidences of redness and swelling at the
PHiD-CV and DTPa-HBV-IPV/Hib vaccination sites, were in
line with previous European primary vaccination studies in
which infants received PHiD-CV or 7vCRM co-administered
with a DTPa-based combination vaccine.15 The incidences
of pain at both injection sites were higher than those re-
ported in the European primary vaccination studies (36.9%
versus 25.8e28.7%).15 While the reason for the higher rate
of pain in the present study remains unclear, differences in
reactogenicity when the same vaccine is used in different
populations have previously been reported.39,40 Higher
rates of local and general symptoms were reported in
Chilean infants in comparison with Belgian infants in a study
of a Hib-tetanus toxoid conjugate and DTP combination
vaccine.39 The investigators regarded this as possibly due to
differences in surveillance practice. As in our study, this
might have been due to the subjective assessment of pain
in small children, which can be influenced by cultural
perceptions of pain.
The frequencies of general symptoms were in line with
other pneumococcal conjugate vaccine studies, with irri-
tability as the most common general symptom followed by
drowsiness.15 There were no reports of grade 3 fever (rectal
temperature > 40 C) and the most frequent unsolicited AE
was upper respiratory tract infection, which was in line
with expected events in the infant population studied.
There were very low incidences of grade 3 unsolicited AEs
and unsolicited AEs considered to be causally related to
vaccination, and no SAEs were considered by the investi-
gator to be causally related to vaccination.
In conclusion, PHiD-CV has been proven to be highly
immunogenic and was well tolerated in Taiwanese infants
when given as a 3-dose primary vaccination co-administered
with routine childhood vaccines within the first 6 months
of life. Strong immune responses were observed against all
10 vaccine pneumococcal serotypes and the NTHi derived
carrier protein (protein D). Immune responses were also
seen against the cross-reactive serotypes 6A and 19A. These
results suggest that this 10-valent pneumococcal conjugate
vaccine will provide effective protection against IPD and
AOM episodes in Taiwanese children.
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